The list of analyst covering Acadia Pharma has grown, and so has the price targets they are anticipating in the future. So, below is a list of a few that have recently updated price projections.
Price Target:
2-24-15 Wainwright: $50.00
2-5-15 Roth: $42.00
11-21-14 Cowen: $46.00
9-22-14 JP Morgan: $33.00
The predominate theme among the analyst is that FDA approval of Nuplazid (pimavanserin) for Parkinson's Disease Psychosis (PDP), is a very high probability event to occur in 2015. Below are the revenue estimates for PDP in the U.S. that Acadia will be addressing with a direct sales force of approximately 135 representatives.
U.S. Peak PDP Revenue:
2-5-15 Roth: $2.7 billion
11-21-14 Cowen: $1.1 billion
9-22-14 JP Morgan: $1.0 billion
US Patent for Nuplazid (pimavanserin) runs to mid 2028.
Bottom Line: Always interesting to see what analyst are thinking with their price targets and revenue estimates. The above revenue estimates exclude Europe and the rest of world for PDP. Also, excludes any revenue for Alzheimer's Disease Psychosis (ADP), Schizophrenia, or sleep maintenance. Thank you for reading.
Price Target:
2-24-15 Wainwright: $50.00
2-5-15 Roth: $42.00
11-21-14 Cowen: $46.00
9-22-14 JP Morgan: $33.00
The predominate theme among the analyst is that FDA approval of Nuplazid (pimavanserin) for Parkinson's Disease Psychosis (PDP), is a very high probability event to occur in 2015. Below are the revenue estimates for PDP in the U.S. that Acadia will be addressing with a direct sales force of approximately 135 representatives.
U.S. Peak PDP Revenue:
2-5-15 Roth: $2.7 billion
11-21-14 Cowen: $1.1 billion
9-22-14 JP Morgan: $1.0 billion
US Patent for Nuplazid (pimavanserin) runs to mid 2028.
Bottom Line: Always interesting to see what analyst are thinking with their price targets and revenue estimates. The above revenue estimates exclude Europe and the rest of world for PDP. Also, excludes any revenue for Alzheimer's Disease Psychosis (ADP), Schizophrenia, or sleep maintenance. Thank you for reading.
No comments:
Post a Comment